OncoCyte Corporation

NASDAQ: OCX · Real-Time Price · USD
3.38
-0.06 (-1.74%)
At close: May 23, 2025, 3:59 PM
3.37
-0.30%
After-hours: May 23, 2025, 04:04 PM EDT

Company Description

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.

The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.

It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.

The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system.

OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OncoCyte Corporation
OncoCyte Corporation logo
Country United States
IPO Date Dec 30, 2015
Industry Biotechnology
Sector Healthcare
Employees 46
CEO Joshua Riggs

Contact Details

Address:
15 Cushing
Irvine, California
United States
Website https://oncocyte.com

Stock Details

Ticker Symbol OCX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001642380
CUSIP Number 68235C107
ISIN Number US68235C2061
Employer ID 27-1041563
SIC Code 2835

Key Executives

Name Position
Dr. Michael D. West Ph.D. Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. & President of Biotime,Inc.
Joshua Riggs President, Chief Executive Officer & Director
Andrea Susan James Chief Financial Officer
Yuh-Min Chiang Ph.D. Chief Technology Officer
Dr. Ekkehard Schutz M.D., Ph.D. Chief Science Officer
Dr. Paul R. Billings FACP, M.D. Consulting Chief Medical Officer
James Liu Vice President of Accounting, Treasurer, Controller & Principal Accounting Officer
Peter Hong Vice President, General Counsel & Secretary
Sandra O'Donald Senior Vice President of Business Operations

Latest SEC Filings

Date Type Title
May 14, 2025 ARS Filing
May 14, 2025 DEFA14A Filing
May 14, 2025 DEF 14A Filing
May 12, 2025 10-Q Quarterly Report
May 12, 2025 8-K Current Report
May 09, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 17, 2025 8-K Current Report
Apr 08, 2025 424B3 Filing
Mar 28, 2025 S-1 Filing
Mar 28, 2025 4 Filing